JUMP REPORT
NOVAVAX (NVAX)
EARNINGS RELEASE - AUGUST 10 (AMC)
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.42/share REV: 39.58/M
___________________________________________________________
LAST QTR: EPS: -.70/share ACTUAL: -.58/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: 1.35/share REV: 234.3/M
____________________________________________________________
FULL YR: EPS: 7.97/share REV: 1,100/M
____________________________________________________________
BEAT/MISS RECORD: 35% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 83.4, -12.9, 7.77
EXPECTED JUMP MOVE THIS QUARTER: 15-20%
——–
*** With market volatility at extremes there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before tradin
Links To Latest News and Headlines
The Nuvaxovid market offers opportunities in booster immunizations, variant-adapted vaccines, and increased global vaccine coverage. Trends include protein-based platforms, adjuvant-enhanced vaccines, and cold-chain distribution. Challenges like tariffs drive domestic manufacturing, while demand rises due to infectious disease prevalence.Dublin, March 13, 2026 (GLOBE NEWSWIRE) — The “Nuvaxovid Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts” has been added to Re
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) is back in focus after Q4 2025 results showed surprise profitability, with revenue of US$147.14 million and net income of US$17.53 million, supported by key vaccine partnerships and milestone payments. See our latest analysis for Novavax. The latest earnings surprise has come after a sharp move in the share price, with a 1 day share price return of a 9.38% decline following a strong 90 day share price return of 43.83% and a 1 year total shareholder return of 21.73%. However,…
Novavax’s modeled fair value has been reset to US$13.78 from US$13.11, a small move that still matters if you are tracking how assumptions are shifting. Behind that change, recent Street research blends cautious optimism with ongoing concern, as analysts rework their views on the COVID franchise, expense profile, and the contribution from licensing income. Read on to see what is driving these revisions and how you can keep up with the evolving story around Novavax. Stay updated as the Fair…
Novavax (NasdaqGS:NVAX) reported a surprise profit for the fourth quarter, alongside revenue that was above prior expectations. The company is shifting its business model by transferring commercialization of its COVID-19 vaccine Nuvaxovid to Sanofi. Novavax plans to focus on a partnership-driven approach centered on milestone payments, royalties, and advancing its pipeline. For you as an investor, the key change is that Novavax is moving away from directly commercializing Nuvaxovid and…
StockJumpers analysis and trade plans are finalized and uploaded generally one house before market cloase (3PM EST) for most events unless noticed.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
Members who are too busy to manual trade can use Trade Assist. For more information visit here
| Avg Daily Volume: 8,831,772 Market Cap: 5.65B Sector: Healthcare Short Interest: 13.87 |
Ticker delayed 20 minutes
NOTICE: All material on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.